BACKGROUND: Radiofrequency catheter ablation (RFCA) for persistent atrial fibrillation (AF) is still challenging even in RFCA-era for AF. The aim of this study was to assess the clinical utility of nifekalant, a pure potassium channel blocker,during RFCA for persistent AF. METHODS AND RESULTS: We retrospectively enrolled 157 consecutive persistentAF patientsundergoing first RFCA procedure withcomplex fractionated atrial electrogram (CFAE)ablation after pulmonary veins isolation and compared outcomes between patientswith (NFK group: N=79) and without (No-NFK group: N=78)additional CFAE ablation using intravenous nifekalant (0.3mg/kg). Primary endpoint was 24-month atrial arrhythmia-free survival post ablation.The prevalence of AF terminationwas significantly higher in NFK group than No-NFK group (64.6% versus 7.7%, P<0.001). Arrhythmia-free survival, however, was not significantly different between 2 groups (61.5% versus 54.1%, P=0.63).There was no significant difference between 2 groups in the prevalence of recurrent atrial tachycardia(25.0% versus 23.5%, P=0.89). Arrhythmia-free survivalin patients with AF termination during procedure was significantly higher thanthose without (73.0% versus 41.0%, P=0.002; adjusted hazard ratio 0.48, 95% confidence interval 0.17-0.84, P=0.02) amongNFK group,but not amongNo-NFK group (66.7% versus 53.2%, P=0.53). CONCLUSIONS: Intravenous nifekalant injection during additional CFAE ablation did not improve sinus maintenancerate after RFCA procedure for AF, but AF termination by nifekalant injection could be a clinical predictor of better success rates after procedure.
BACKGROUND: Radiofrequency catheter ablation (RFCA) for persistent atrial fibrillation (AF) is still challenging even in RFCA-era for AF. The aim of this study was to assess the clinical utility of nifekalant, a pure potassium channel blocker,during RFCA for persistent AF. METHODS AND RESULTS: We retrospectively enrolled 157 consecutive persistentAF patientsundergoing first RFCA procedure withcomplex fractionated atrial electrogram (CFAE)ablation after pulmonary veins isolation and compared outcomes between patientswith (NFK group: N=79) and without (No-NFK group: N=78)additional CFAE ablation using intravenous nifekalant (0.3mg/kg). Primary endpoint was 24-month atrial arrhythmia-free survival post ablation.The prevalence of AF terminationwas significantly higher in NFK group than No-NFK group (64.6% versus 7.7%, P<0.001). Arrhythmia-free survival, however, was not significantly different between 2 groups (61.5% versus 54.1%, P=0.63).There was no significant difference between 2 groups in the prevalence of recurrent atrial tachycardia(25.0% versus 23.5%, P=0.89). Arrhythmia-free survivalin patients with AF termination during procedure was significantly higher thanthose without (73.0% versus 41.0%, P=0.002; adjusted hazard ratio 0.48, 95% confidence interval 0.17-0.84, P=0.02) amongNFK group,but not amongNo-NFK group (66.7% versus 53.2%, P=0.53). CONCLUSIONS: Intravenous nifekalant injection during additional CFAE ablation did not improve sinus maintenancerate after RFCA procedure for AF, but AF termination by nifekalant injection could be a clinical predictor of better success rates after procedure.
Authors: Hakan Oral; Carlo Pappone; Aman Chugh; Eric Good; Frank Bogun; Frank Pelosi; Eric R Bates; Michael H Lehmann; Gabriele Vicedomini; Giuseppe Augello; Eustachio Agricola; Simone Sala; Vincenzo Santinelli; Fred Morady Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245
Authors: Antoine H G Driessen; Wouter R Berger; Sébastien P J Krul; Nicoline W E van den Berg; Jolien Neefs; Femke R Piersma; Dean R P P Chan Pin Yin; Jonas S S G de Jong; WimJan P van Boven; Joris R de Groot Journal: J Am Coll Cardiol Date: 2016-09-13 Impact factor: 24.094
Authors: Jonathan P Piccini; Renato D Lopes; Melissa H Kong; Vic Hasselblad; Kevin Jackson; Sana M Al-Khatib Journal: Circ Arrhythm Electrophysiol Date: 2009-12
Authors: Xu Ping Li; Jian Zeng Dong; Xing Peng Liu; De Yong Long; Rong Hui Yu; Yin Tian; Ri Bo Tang; Bin Zheng; Fu Li Hu; Li Sheng Shi; Hua He; Chang Sheng Ma Journal: Circ J Date: 2008-07 Impact factor: 2.993
Authors: Zhibing Lu; Benjamin J Scherlag; Jiaxiong Lin; Lilei Yu; Ji-Hong Guo; Guodong Niu; Warren M Jackman; Ralph Lazzara; Hong Jiang; Sunny S Po Journal: Cardiovasc Res Date: 2009-06-11 Impact factor: 10.787
Authors: Sheldon M Singh; Andre D'Avila; Steven J Kim; Christopher Houghtaling; Srinivas R Dukkipati; Vivek Y Reddy Journal: J Cardiovasc Electrophysiol Date: 2009-12-21